Alarm sounded on copycat drugs regulation – Financial Times
It also underscored the importance of a provision in the 2010 US healthcare law that created a regulatory pathway to approve copycat versions of biotech drugs – known as biosimilars – at the nation’s Food and Drug Administration (FDA). If the US ...
Subscribe to LegalLaw247.Com Newsletter
